Emerging data suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to provide a significant advancement for weight management . Initial patient tests have shown considerable reductions in abdominal fat , potentially exceeding other weight-loss therapies . Nevertheless , additional stud